Sprint Bioscience AB (publ) (FRA:5JA1)

Sprint Bioscience AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	167.17	65.64	50.49	0.08	35.11
Other Revenue	0.48	0.5	1.2	-	-0.09
Revenue	167.65	66.14	51.69	0.08	35.03
Revenue Growth (YoY)	153.47%	27.97%	62171.08%	-99.76%	82.48%
Cost of Revenue	13.08	28.34	8.7	12.93	10.44
Gross Profit	154.57	37.8	42.99	-12.85	24.59
Selling, General & Admin	55.69	56.28	45.07	47.44	49.47
Other Operating Expenses	0.52	-0.67	-1.21	-0.29	-
Operating Expenses	57.28	56.57	44.31	47.77	50.06
Operating Income	97.29	-18.77	-1.32	-60.62	-25.47
Interest Expense	-	-0.04	-	-0	-0.27
Interest & Investment Income	-	1.43	0.79	-	-
Currency Exchange Gain (Loss)	-	-0.9	0.09	0.45	0.69
Other Non Operating Income (Expenses)	-5.56	-	-	-0	-0.04
EBT Excluding Unusual Items	91.74	-18.28	-0.44	-60.17	-25.08
Pretax Income	91.74	-18.28	-0.44	-60.17	-25.08
Net Income	91.74	-18.28	-0.44	-60.17	-25.08
Net Income to Common	91.74	-18.28	-0.44	-60.17	-25.08
Shares Outstanding (Basic)	93	70	70	42	29
Shares Outstanding (Diluted)	93	70	70	42	29
Shares Change (YoY)	32.63%	0.01%	65.98%	45.85%	71.85%
EPS (Basic)	0.99	-0.26	-0.01	-1.43	-0.87
EPS (Diluted)	0.98	-0.26	-0.01	-1.43	-0.87
Free Cash Flow	83.44	-24.65	20.42	-59.05	-42.82
Free Cash Flow Per Share	0.90	-0.35	0.29	-1.40	-1.49
Gross Margin	92.20%	57.16%	83.17%	-	70.21%
Operating Margin	58.03%	-28.37%	-2.56%	-73031.32%	-72.70%
Profit Margin	54.72%	-27.63%	-0.85%	-72493.98%	-71.61%
Free Cash Flow Margin	49.77%	-37.27%	39.50%	-71149.40%	-122.26%
EBITDA	98.37	-17.81	-0.88	-60	-24.88
EBITDA Margin	58.67%	-26.93%	-1.70%	-	-71.02%
D&A For EBITDA	1.07	0.96	0.45	0.62	0.59
EBIT	97.29	-18.77	-1.32	-60.62	-25.47
EBIT Margin	58.03%	-28.37%	-2.56%	-	-72.70%
Revenue as Reported	167.65	67.44	54.32	0.45	35.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.